Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis

Autores
Sánchez, A.; Brun, L. R.; Salerni, H.; Costanzo, P. R.; González, D.; Bagur, A.; Oliveri, B.; Zanchetta, M. B.; Farías, V.; Maffei, L.; Premrou, V.; Mansur, José Luis; Larroudé, M. S.; Sarli, M. A.; Rey, P.; Ulla, M. R.; Pavlove, M. M.; Karlsbrum, S.; Brance, M. L.
Año de publicación
2016
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BPprior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMDand decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.
Facultad de Ciencias Médicas
Materia
Medicina
denosumab
bone mineral density
bone turnover markers
osteoporosis
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by/4.0/
Repositorio
SEDICI (UNLP)
Institución
Universidad Nacional de La Plata
OAI Identificador
oai:sedici.unlp.edu.ar:10915/151985
Acceder
id SEDICI_0345601ab111c7755ae6708fa6906366
oai_identifier_str oai:sedici.unlp.edu.ar:10915/151985
network_acronym_str SEDICI
repository_id_str 1329
network_name_str SEDICI (UNLP)
spelling Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with OsteoporosisSánchez, A.Brun, L. R.Salerni, H.Costanzo, P. R.González, D.Bagur, A.Oliveri, B.Zanchetta, M. B.Farías, V.Maffei, L.Premrou, V.Mansur, José LuisLarroudé, M. S.Sarli, M. A.Rey, P.Ulla, M. R.Pavlove, M. M.Karlsbrum, S.Brance, M. L.Medicinadenosumabbone mineral densitybone turnover markersosteoporosisThe aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BPprior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMDand decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.Facultad de Ciencias Médicas2016info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://sedici.unlp.edu.ar/handle/10915/151985enginfo:eu-repo/semantics/altIdentifier/issn/2090-8059info:eu-repo/semantics/altIdentifier/issn/2042-0064info:eu-repo/semantics/altIdentifier/doi/10.1155/2016/8738959info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/Creative Commons Attribution 4.0 International (CC BY 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-09-29T11:39:11Zoai:sedici.unlp.edu.ar:10915/151985Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-09-29 11:39:11.908SEDICI (UNLP) - Universidad Nacional de La Platafalse
dc.title.none.fl_str_mv Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
title Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
spellingShingle Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
Sánchez, A.
Medicina
denosumab
bone mineral density
bone turnover markers
osteoporosis
title_short Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
title_full Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
title_fullStr Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
title_full_unstemmed Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
title_sort Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
dc.creator.none.fl_str_mv Sánchez, A.
Brun, L. R.
Salerni, H.
Costanzo, P. R.
González, D.
Bagur, A.
Oliveri, B.
Zanchetta, M. B.
Farías, V.
Maffei, L.
Premrou, V.
Mansur, José Luis
Larroudé, M. S.
Sarli, M. A.
Rey, P.
Ulla, M. R.
Pavlove, M. M.
Karlsbrum, S.
Brance, M. L.
author Sánchez, A.
author_facet Sánchez, A.
Brun, L. R.
Salerni, H.
Costanzo, P. R.
González, D.
Bagur, A.
Oliveri, B.
Zanchetta, M. B.
Farías, V.
Maffei, L.
Premrou, V.
Mansur, José Luis
Larroudé, M. S.
Sarli, M. A.
Rey, P.
Ulla, M. R.
Pavlove, M. M.
Karlsbrum, S.
Brance, M. L.
author_role author
author2 Brun, L. R.
Salerni, H.
Costanzo, P. R.
González, D.
Bagur, A.
Oliveri, B.
Zanchetta, M. B.
Farías, V.
Maffei, L.
Premrou, V.
Mansur, José Luis
Larroudé, M. S.
Sarli, M. A.
Rey, P.
Ulla, M. R.
Pavlove, M. M.
Karlsbrum, S.
Brance, M. L.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Medicina
denosumab
bone mineral density
bone turnover markers
osteoporosis
topic Medicina
denosumab
bone mineral density
bone turnover markers
osteoporosis
dc.description.none.fl_txt_mv The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BPprior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMDand decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.
Facultad de Ciencias Médicas
description The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 425 postmenopausal women treated with Dmab for 1 year in clinical practice conditions in specialized centers from Argentina. Participants were also divided according to previous bisphosphonate treatment into BP-naïve and BP-prior. A control group of patients treated with BP not switched to Dmab matched by sex, age, and body mass index was used. Data are expressed as mean ± SEM. After 1 year of treatment with Dmab the bone formation markers total alkaline phosphatase and osteocalcin were significantly decreased (23.36% and 43.97%, resp.), as was the bone resorption marker s-CTX (69.61%). Significant increases in BMD were observed at the lumbar spine, femoral neck, and total hip without differences between BP-naïve and BP-prior. A better BMD response was found in BPprior group compared with BP treated patients not switched to Dmab. Conclusion. Dmab treatment increased BMDand decreased bone turnover markers in the whole group, with similar response in BP-naïve and BP-prior patients. A better BMD response in BP-prior patients versus BP treated patients not switched to Dmab was observed.
publishDate 2016
dc.date.none.fl_str_mv 2016
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Articulo
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://sedici.unlp.edu.ar/handle/10915/151985
url http://sedici.unlp.edu.ar/handle/10915/151985
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/issn/2090-8059
info:eu-repo/semantics/altIdentifier/issn/2042-0064
info:eu-repo/semantics/altIdentifier/doi/10.1155/2016/8738959
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:SEDICI (UNLP)
instname:Universidad Nacional de La Plata
instacron:UNLP
reponame_str SEDICI (UNLP)
collection SEDICI (UNLP)
instname_str Universidad Nacional de La Plata
instacron_str UNLP
institution UNLP
repository.name.fl_str_mv SEDICI (UNLP) - Universidad Nacional de La Plata
repository.mail.fl_str_mv alira@sedici.unlp.edu.ar
_version_ 1844616266378117120
score 13.069144

Publicaciones similares